Kolexia
Beal Ardisson Dominique Oncologie médicale
Beal Ardisson Dominique
Oncologie médicale
Selarl Oncologie Beal Derbel Bally
Lyon, France
65 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Tumeurs de la prostate Métastase tumorale Tumeurs prostatiques résistantes à la castration Carcinome épithélial de l'ovaire Carcinomes Tumeurs des glandes endocrines Tumeurs de l'ovaire Effets secondaires indésirables des médicaments

Collaborateurs

Voir plus
Mammar Vincent
Mammar Vincent
Selarl Orlam, Mâcon, France
Mere Pascale
Mere Pascale
Centre Léon-Bérard, Lyon, France
Desrame Jerome
Desrame Jerome
Clinique Du Parc Lyon, Lyon, France
Bauler Stéphanie
Bauler Stéphanie
Gcs Medipole Lyon-villeurbanne - Siege, Villeurbanne, France

Industries

Voir plus
MSD
14 collaboration(s)
Dernière en 2023
Janssen
9 collaboration(s)
Dernière en 2023
Novartis
5 collaboration(s)
Dernière en 2023
AstraZeneca
4 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer: Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy With the Bevacizumab + Taxane Versus Bevacizumab + Substituting Exemestane in Patients With Metastatic Breast Cancer or Locally Advanced With Estrogen Receptor Positive and Having at Least a Stable Disease After 16 to 18 Weeks of Treatment With Bevacizumab + Taxane.
Essai Clinique (ARCAGY/ GINECO GROUP)   05 septembre 2023
CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients.
Breast cancer (Tokyo, Japan)   05 janvier 2023
Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first-line setting. Exhaustive analysis from the Rhone-Alpes region.
European journal of cancer care   07 septembre 2020
Impact of Abiraterone Acetate plus Prednisone or Enzalutamide on Patient-reported Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer: Final 12-mo Analysis from the Observational AQUARiUS Study.
European urology   05 octobre 2019
Le dépistage du cancer du sein - Octobre Rose
Youtube @ Ramsay Santé   01 octobre 2019
A GINECO randomized phase II assessing addition of an aromatase inhibitor to oral vinorelbine in pretreated metastatic breast cancer patients.
2019 ASCO Annual Meeting I   26 mai 2019
AQUARiUS: Prospective Multi-country Observational Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Patient-reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Patients
Essai Clinique (Janssen)   23 mai 2019
Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study.
ESMO open   03 août 2018
Six-month patient-reported outcome (PRO) results from AQUARiUS, a prospective, observational, multicenter phase 4 study in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate + prednisone (AAP) or enzalutamide (ENZ).
2018 ASCO Annual Meeting I   01 juin 2018
Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France.
BMC health services research   04 janvier 2018